Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

11.70USD
4:00pm EDT
Change (% chg)

$-0.37 (-3.07%)
Prev Close
$12.07
Open
$12.07
Day's High
$12.10
Day's Low
$11.68
Volume
479,865
Avg. Vol
931,751
52-wk High
$13.38
52-wk Low
$5.36

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $2,320.31
Shares Outstanding(Mil.): 192.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 91.69 16.82
EPS (TTM): -- -- --
ROI: -- 2.46 11.24
ROE: -- 3.30 15.07

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

Sep 13 2017

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

Sep 12 2017

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

Aug 09 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Jul 18 2017

BRIEF-Array Biopharma submits new drug applications to FDA

* Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma

Jul 05 2017

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

May 31 2017

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

May 31 2017

BRIEF-Array BioPharma and Bristol-Myers Squibb announce strategic collaboration

* Array bioPharma and Bristol-Myers Squibb announce strategic collaboration

May 30 2017

BRIEF-Array BioPharma Q3 loss per share $0.21

* Array biopharma reports financial results for the third quarter of fiscal 2017

May 10 2017

Competitors

Earnings vs. Estimates